Skip to search formSkip to main contentSkip to account menu

Anti-CD33 Antibody-drug Conjugate IMGN779

Known as: ADC IMGN779, Anti-CD33 ADC IMGN779, IMGN779 
An antibody-drug conjugate (ADC) consisting of the humanized monoclonal antibody Z4681A conjugated, via a cleavable disulfide linker, to the… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Tiroid Nodüllerinde Malign ve Benign Ayrımında Difüzyon Ağırlıklı Manyetik Rezonans İncelemenin Yeri
Oz Amac: Bu calismanin amaci, Difuzyon Agirlikli Manyetik Rezonans Goruntulemenin (DAMRG) tiroid nodullerinde malign-benign… 
2018
2018
Abstract 2820: Synergistic antileukemic activity of the antibody-drug conjugate (IMGN779) combined with PARP inhibition in preclinical human acute myeloid leukemia models
Background: Acute myeloid leukemia (AML) is an aggressive hematologic malignancy of immature myeloid cells. Antibody-drug… 
2016
2016
Combining IMGN779, a Novel Anti-CD33 Antibody-Drug Conjugate (ADC), with the PARP Inhibitor, Olaparib, Results in Enhanced Anti-Tumor Activity in Preclinical Acute Myeloid Leukemia (AML) Models
Background: New therapies for AML are urgently needed. IMGN779 is a novel CD33-targeting ADC that utilizes as the cytotoxic agent… 
2015
2015
Abstract 4504: Plasma pharmacokinetics and tumor accumulation in mice of IMGN779, an antibody-drug conjugate for acute myeloid leukemia
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA IMGN779, an antibody-drug conjugate (ADC… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)